143 results on '"Tomoki, Tamura"'
Search Results
2. Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study.
- Author
-
Kohei Miyake, Satoru Senoo, Ritsuya Shiiba, Junko Itano, Goro Kimura, Tatsuyuki Kawahara, Tomoki Tamura, Kenichiro Kudo, Tetsuji Kawamura, Yasuharu Nakahara, Hisao Higo, Daisuke Himeji, Nagio Takigawa, Nobuaki Miyahara, and Okayama Respiratory Disease Study Group (ORDSG)
- Subjects
Medicine ,Science - Abstract
ObjectiveLong-term steroid use increases the risk of developing Pneumocystis pneumonia (PcP), but there are limited reports on the relation of long-term steroid and PcP mortality.MethodsRetrospective multicenter study to identify risk factors for PcP mortality, including average steroid dose before the first visit for PcP in non-human immunodeficiency virus (HIV)-PcP patients. We generated receiver operating characteristic (ROC) curves for 90-day all-cause mortality and the mean daily steroid dose per unit body weight in the preceding 10 to 90 days in 10-day increments. Patients were dichotomized by 90-day mortality and propensity score-based stabilized inverse probability of treatment weighting (IPTW) adjusted covariates of age, sex, and underlying disease. Multivariate analysis with logistic regression assessed whether long-term corticosteroid use affected outcome.ResultsOf 133 patients with non-HIV-PcP, 37 died within 90 days of initial diagnosis. The area under the ROC curve for 1-40 days was highest, and the optimal cutoff point of median adjunctive corticosteroid dosage was 0.34 mg/kg/day. Past steroid dose, underlying interstitial lung disease and emphysema, lower serum albumin and lower lymphocyte count, higher lactate dehydrogenase, use of therapeutic pentamidine and therapeutic high-dose steroids were all significantly associated with mortality. Underlying autoimmune disease, past immunosuppressant use, and a longer time from onset to start of treatment, were associated lower mortality. Logistic regression analysis after adjusting for age, sex, and underlying disease with IPTW revealed that steroid dose 1-40 days before the first visit for PcP (per 0.1 mg/kg/day increment, odds ratio 1.36 [95% confidence interval = 1.16-1.66], PConclusionA steroid dose before PcP onset was strongly associated with 90-day mortality in non-HIV-PcP patients, emphasizing the importance of appropriate prophylaxis especially in this population.
- Published
- 2024
- Full Text
- View/download PDF
3. Safety of anti‐SARS‐CoV‐2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient‐reported outcome study
- Author
-
Daijiro Harada, Tomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, Shoichi Kuyama, Sayaka Tachibana, Koji Inoue, Kenichi Chikamori, Kenichiro Kudo, Nobuaki Ochi, Yoshinobu Maeda, and Katsuyuki Kiura
- Subjects
anticancer drugs ,COVID‐19 ,lung cancer ,SARS‐CoV‐2 ,vaccine safety ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background COVID‐19 incidence is high in patients with cancer. The fatality rate was high for the Delta variant, necessitating infection prevention by vaccination. This study evaluated the safety of a SARS‐CoV‐2 vaccine in patients with advanced lung cancer receiving anticancer therapy. Methods We prospectively enrolled patients receiving anticancer drugs for advanced lung cancer and planning SARS‐CoV‐2 vaccination. Early side effects within 7 days of vaccination were evaluated using patient‐reported outcome (PRO) surveys. Chi‐square test and multivariate logistic regression analyses were used. Results Post‐vaccination PROs were collected from 406 patients (252 were males). The mean age was 72 years. Treatment at the time of initial vaccination included chemotherapy, immune checkpoint inhibitors (ICI), a combination of chemotherapy and ICI, targeted therapy including tyrosine kinase inhibitors, and others in 115, 93, 45, 147, and six cases, respectively. The vaccines administered were BNT162b2 and mRNA273 in 361 and three cases, respectively and unknown in 42 cases. A total of 16.1% of patients developed fever (38°C) after the second mRNA vaccination (95% confidence interval: 12.6%–20.1%). This rate is comparable to data previously reported in 120 patients and slightly higher than that of healthy participants of the BNT162b2 study. Patients receiving treatment with cytotoxic anticancer agents were more likely to have high fever. Multivariate analysis showed no correlation between fever frequency and patient background. No serious initial adverse events due to vaccination were observed. Conclusions Anti‐SARS‐CoV‐2 mRNA vaccination is safe; however, post‐vaccination fever is more common in patients undergoing lung cancer treatment than in healthy individuals.
- Published
- 2023
- Full Text
- View/download PDF
4. Short‐term safety of an anti‐severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study
- Author
-
Tomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, Shoichi Kuyama, Sayaka Tachibana, Koji Inoue, Kenichi Chikamori, Kenichiro Kudo, Nobuaki Ochi, Daijiro Harada, Yoshinobu Maeda, and Katsuyuki Kiura
- Subjects
anticancer drugs ,COVID‐19 ,lung cancer ,SARS‐CoV‐2 ,vaccine ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Since 2020, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become prevalent worldwide. In severe cases, the case fatality rate is high, and vaccine prevention is important. This study evaluated the safety of receiving SARS‐CoV‐2 vaccine in patients with advanced lung cancer receiving anticancer therapy. Methods We prospectively enrolled patients receiving anticancer drugs for advanced lung cancer who planned to receive SARS‐CoV‐2 vaccination. Early adverse events within 7 days of vaccine injection were evaluated using patient‐reported surveys. The chi‐square test and multivariate logistic regression analyses were used. Results Among 120 patients receiving lung cancer treatment, 73 were men; the mean age of the patients was 73.5 years. The treatments received for lung cancer at the time of the first vaccine injection were chemotherapy, ICIs, combined chemotherapy and ICIs, and targeted therapies, including tyrosine kinase inhibitors, in 30, 28, 17, and 45 patients, respectively. All patients received SARS‐CoV‐2 messenger RNA (mRNA) vaccine. After the second mRNA vaccine dose, 15.4% of patients had fever of 38°C (95% confidence interval: 9.34%–23.2%); this rate was slightly higher than that for healthy participants at the time of the BNT162b2 trial. Patients treated with cytotoxic anticancer drugs tended to have high fever. In the multivariate analyses, male sex was associated with higher fever frequencies. However, there were no serious early adverse events due to vaccination. Conclusions Anti‐SARS‐CoV‐2 mRNA vaccination tends to be safe, but fever following vaccination tends to be more common among patients undergoing lung cancer treatment than among healthy individuals.
- Published
- 2022
- Full Text
- View/download PDF
5. A case of synovitis-acne-pustulosis-hyperostosis-osteitis syndrome with right pleural effusion
- Author
-
Takayuki Kakimoto, Tomoki Tamura, Taisaku Koyanagi, Takahiro Umeno, Kazuya Nishii, and Shoichi Kuyama
- Subjects
Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome ,Pleural effusion ,Bull's head sign ,Diseases of the respiratory system ,RC705-779 - Abstract
A 79-year-old man presented with fatigue and right shoulder pain. Computed tomography revealed right pleural effusion and osteosclerosis of the sternoclavicular joint. There were no signs of malignancy or infection in the pleural fluid studies. His bone scintigraphy exhibited the “bull's head sign.” Despite the absence of skin lesions, he was diagnosed with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome. Remission was achieved after treatment with non-steroidal anti-inflammatory drugs and oral prednisolone.SAPHO syndrome causes pleural effusion, even in patients without skin lesions. Bone scintigraphy should be considered in the workup for patients with unexplained pleural effusion.
- Published
- 2023
- Full Text
- View/download PDF
6. A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
- Author
-
Tomoki Tamura, Sakura Hata, Takahiro Baba, Taisaku Koyanagi, Takahiro Umeno, Kazuya Nishii, and Shoichi Kuyama
- Subjects
Non-small cell lung cancer ,Adverse event ,Skin rash ,Tepotinib ,Desensitization ,Diseases of the respiratory system ,RC705-779 - Abstract
Tepotinib is one of the key drugs for MET exon 14-skipping mutation-positive non-small cell lung cancer (NSCLC). The main adverse event of tepotinib treatment is edema. Rash is a rare adverse event, affecting only 0.7% of patients. We report a case of successful desensitization after skin rash caused by tepotinib. A 61-year-old male was treated with tepotinib 500 mg as second-line therapy for NSCLC with MET exon 14-skipping mutation. Treatment was discontinued on day 12 due to grade 3 erythema throughout the body. After improvement of the skin rash, he was started on 250 mg tepotinib with an oral antihistamine and topical steroid. Treatment was discontinued on day 11 due to skin rash exacerbation. One month of treatment-free follow-up showed skin rash improvement but lung carcinoma growth. Tepotinib desensitization therapy was started at a dose of 12.5 mg and gradually increased to 250 mg/day. The patient has since continued tepotinib treatment without skin rashes. Desensitization therapy may be effective for managing skin rash due to tepotinib.
- Published
- 2023
- Full Text
- View/download PDF
7. Case report a case of durvalumab induced aplastic anemia after chemoradiotherapy for NSCLC
- Author
-
Kengo Mori, Kazuya Nishii, Wataru Kitamura, Tomohiro Urata, Takahiro Baba, Hiroki Omori, Masamoto Nakanishi, Tomoki Tamura, and Shoichi Kuyama
- Subjects
Durvalumab ,PD-L1 ,Aplastic anemia ,Immune-related adverse event ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
A 74-year-old woman with squamous cell lung cancer (cT3N1M0, c-stage IIIA) was treated with durvalumab after chemoradiotherapy. At the beginning of the fourth treatment, Grade 2 (Common Terminology Criteria for Adverse Events ver5.0) radiotherapy-induced pneumonitis occurred, followed by sudden thrombocytopenia of Grade 4 (14,000/μL) a month later, and two weeks later, platelet and white blood cell counts decreased to 1,000/μL and 1,110/μL, respectively. Bone marrow biopsy showed markedly hypoplastic marrow without dysplasia, and we diagnosed aplastic anemia secondary to durvalumab. The patient required frequent granulocyte colony-stimulating factor (G-CSF) injections and platelet transfusions. From the beginning of treatment, the patient responded poorly to platelet transfusions, and anti-human leukocyte antigen (HLA) antibodies were detected. After multidisciplinary treatment, including the use of HLA-matched platelet transfusions, platelets and white blood cells gradually recovered from platelet transfusion dependence approximately two months after the onset of aplastic anemia. Here, we report the first case of durvalumab-induced aplastic anemia.
- Published
- 2022
- Full Text
- View/download PDF
8. Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report
- Author
-
Keita Kawakado, Tomoki Tamura, Masamoto Nakanishi, Go Makimoto, Yumiko Sato, and Shoichi Kuyama
- Subjects
carboplatin ,case report ,pembrolizumab ,pemetrexed ,primary salivary gland‐type tumor of the lung ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Primary salivary gland‐type tumors of the lung are rare, accounting for
- Published
- 2021
- Full Text
- View/download PDF
9. Limited effect of afatinib in a non‐small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report
- Author
-
Tomoki Tamura, Keita Kawakado, Go Makimoto, Masamoto Nakanishi, and Shoichi Kuyama
- Subjects
afatinib ,brain metastasis ,epidermal growth factor receptor uncommon mutation ,K860I ,second‐generation EGFR‐tyrosine kinase inhibitors ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are key drugs in the treatment of non‐small cell lung cancer (NSCLC) patients with EGFR mutations; however, first‐generation EGFR‐TKIs, such as gefitinib and erlotinib, are not effective in patients with uncommon EGFR mutations. In contrast, efficacy of afatinib has been reported in some types of uncommon EGFR mutation such as G710X, L861Q. The effect of afatinib in NSCLC patients with the EGFR K860I mutation has been shown in vitro, but its clinical efficacy has not been demonstrated. Here, we report the experience of afatinib administration in an NSCLC patient with an EGFR K860I mutation. A 69‐year‐old woman presented with right hemiplegia and dysarthria. Multiple brain and lung tumors were observed. She underwent craniotomy and was diagnosed with lung adenocarcinoma. After stereotactic brain radiation therapy, cisplatin, pemetrexed, and bevacizumab combination therapy was initiated. Unfortunately, she was unable to continue chemotherapy as she had an intestinal perforation after two cycles. After five months, recurrence of multiple brain metastases and an increase in primary lung cancer were confirmed. Next‐generation sequencing (NGS) was performed in a clinical trial, and an EGFR K860I mutation was detected in her tumor. Afatinib was administered and the primary lung tumor shrank, but multiple brain metastases were exacerbated. After irradiation of the brain, afatinib administration was continued. In conclusion, afatinib may show an effect in NSCLC patients with the EGFR K860I mutation, but its efficacy is limited.
- Published
- 2021
- Full Text
- View/download PDF
10. Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
- Author
-
Go Makimoto, Keita Kawakado, Masamoto Nakanishi, Tomoki Tamura, and Shoichi Kuyama
- Subjects
alectinib ,lorlatinib ,non-small-cell lung cancer ,anaplastic lymphoma kinase ,hepatotoxicity ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Alectinib is a key drug for treating anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib. Herein, we describe a case of ALK-positive adenocarcinoma successfully treated with lorlatinib after developing alectinib-induced hepatotoxicity. A 57-year-old Japanese man received alectinib as first-line therapy for ALK-positive NSCLC. After 79 days, alectinib was discontinued because of hepatotoxicity and later restarted at 150 mg/day, inducing hepatotoxicity again after 64 days. Switching to lorlatinib treatment (continued for >4 months) caused no severe adverse effects. Hence, lorlatinib may be useful for patients experiencing alectinib-induced hepatotoxicity.
- Published
- 2021
- Full Text
- View/download PDF
11. A case of immunoglobulin G4-Related disease with pleural effusion, requiring exclusion of tuberculous pleurisy
- Author
-
Susumu Doita, Tomoki Tamura, Takahiro Baba, Hiroki Oomori, Kazuya Nishii, Masamoto Nakanishi, and Shoichi Kuyama
- Subjects
Immunoglobulin G4-related pleurisy ,Adenosine deaminase ,Tuberculosis ,Diseases of the respiratory system ,RC705-779 - Abstract
Immunoglobulin G4 (IgG4)-related pleurisy is a rare type of IgG4-related disease. We present the case of a 69-year-old woman with left pleural effusion and elevated adenosine deaminase levels. Initially, tuberculous pleuritis was suspected; however, the bacterial cultures and polymerase chain reaction test results for tuberculosis were negative. Thoracoscopic pleural biopsy revealed dense lymphocytic infiltrates with large numbers of IgG4-positive plasma cells. The ratio of IgG4-positive to IgG-positive plasma cells exceeded 40%. The patient was diagnosed with IgG4-related disease.
- Published
- 2022
- Full Text
- View/download PDF
12. Successful corticosteroid treatment of necrotizing sarcoid granulomatosis associated with tracheal lesion recurred after a surgical lung biopsy
- Author
-
Go Makimoto, Keita Kawakado, Masamoto Nakanishi, Tomoki Tamura, Yumiko Sato, and Shoichi Kuyama
- Subjects
Necrotizing sarcoid granulomatosis ,Corticosteroid ,Tracheal lesion ,Recurrence ,Diseases of the respiratory system ,RC705-779 - Abstract
Necrotizing sarcoid granulomatosis (NSG) is a rare disease that presents with nodular lung lesions and necrosis. The pathology is consistent with sarcoidosis, but the necrosis can lead to a diagnosis of tuberculosis. Herein, we report a rare case of NSG that recurred four years after the initial diagnosis was made by surgical lung biopsy. A 51-year-old woman was initially referred to our hospital for the evaluation of multiple lung nodules. The pathological evaluation of a lung biopsy showed granulomas with necrosis and the infiltration of lymphocytes; thus, she was diagnosed with NSG. The lung nodules gradually improved after the diagnosis and we continued to follow her even though she did not require treatment. Four years after her initial diagnosis, she complained of back pain. Upon evaluation, we found that multiple lung nodules had recurred. Bronchoscopy also revealed a tracheal polypoid lesion, which showed granulomas with necrosis pathologically. Therefore, we diagnosed her with the recurrence of NSG. After the corticosteroid therapy, multiple lung nodules drastically improved. NSG patients should be carefully followed-up over several years, even if they do not require treatment.
- Published
- 2021
- Full Text
- View/download PDF
13. Successful transcatheter arterial embolization of asymptomatic aneurysm associated with left inferior phrenic artery-to-left pulmonary artery fistula: A case report
- Author
-
Keita Kawakado, Takayuki Yabuki, Tatsuya Nishi, Masamoto Nakanishi, Go Makimoto, Tomoki Tamura, and Shoichi Kuyama
- Subjects
Aneurysm ,Inferior phrenic artery-to-pulmonary artery fistula ,Transcatheter arterial embolization ,Diseases of the respiratory system ,RC705-779 - Abstract
Cases of inferior phrenic artery-to-pulmonary artery fistulas and those complicated by massive hemoptysis have been rarely reported. A 38-year-old man presented to our hospital with a chief complaint of coughing. Computed tomography (CT) revealed a nodule in the left lower lobe, and contrast-enhanced CT showed inflow of contrast medium into the nodule. CT angiography detected an aneurysm associated with a left inferior phrenic artery-to-left pulmonary artery fistula. Transcatheter arterial embolization (TAE) was performed to prevent hemoptysis. Hemoptysis did not occur during the 2-year follow-up. We report a rare case of asymptomatic aneurysm associated with a left inferior phrenic artery-to-left pulmonary artery fistula, which was successfully treated using TAE to prevent hemoptysis.
- Published
- 2021
- Full Text
- View/download PDF
14. Successful Management of Acute Type A Aortic Dissection with Spinal Cord Ischemia: A 3-Case Series
- Author
-
Tomoki Tamura, Yurie Otomo, and Tetsuya Horai
- Subjects
General Medicine - Published
- 2023
- Full Text
- View/download PDF
15. Surgical Case of Tuberculous Abdominal Aortic Aneurysm and Thoracic Aortic Aneurysm with Miliary Tuberculosis
- Author
-
Tomoki Tamura, Yuta Murai, Tsuyoshi Taketani, and Tetsuya Horai
- Subjects
General Medicine - Published
- 2023
- Full Text
- View/download PDF
16. Safety of <scp>anti‐SARS‐CoV</scp> ‐2 messenger <scp>RNA</scp> vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, <scp>patient‐reported</scp> outcome study
- Author
-
Daijiro Harada, Tomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, Shoichi Kuyama, Sayaka Tachibana, Koji Inoue, Kenichi Chikamori, Kenichiro Kudo, Nobuaki Ochi, Yoshinobu Maeda, and Katsuyuki Kiura
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,General Medicine - Published
- 2022
- Full Text
- View/download PDF
17. Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
- Author
-
Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, Shoichi Kuyama, Koji Inoue, Kenichi Gemba, Hirohisa Ichikawa, Yuka Kato, Naohiro Oda, Isao Oze, Tomoki Tamura, Toshiyuki Kozuki, Takahiro Umeno, Toshio Kubo, Katsuyuki Hotta, Akihiro Bessho, Yoshinobu Maeda, and Katsuyuki Kiura
- Subjects
Oncology ,Surgery ,Hematology ,General Medicine - Published
- 2022
- Full Text
- View/download PDF
18. Propionibacterium acnes-derived insoluble immune complexes in sinus macrophages of lymph nodes affected by sarcoidosis.
- Author
-
Yoshimi Suzuki, Keisuke Uchida, Tamiko Takemura, Masaki Sekine, Tomoki Tamura, Asuka Furukawa, Akira Hebisawa, Yumi Sakakibara, Nobuyasu Awano, Tomonari Amano, Daisuke Kobayashi, Mariko Negi, Tomoya Kakegawa, Yuriko Wada, Takashi Ito, Takashige Suzuki, Takumi Akashi, and Yoshinobu Eishi
- Subjects
Medicine ,Science - Abstract
Propionibacterium acnes is thought to be a causative agent of sarcoidosis. Patients with sarcoidosis have circulating immune complexes. We attempted to detect P. acnes-derived immune complexes in sarcoid lesions.We evaluated formalin-fixed and paraffin-embedded lymph node samples from 38 sarcoidosis patients and 90 non-sarcoidosis patients (27 patients with necrotizing lymphadenitis, 28 patients with reactive lymphadenitis, 16 patients with colon cancer, 19 patients with gastric cancer) by immunohistochemistry using anti-human immunoglobulins (IgG, IgA, and IgM) and complement (C1q and C3c) antibodies, and a P. acnes-specific monoclonal antibody (PAB antibody) that reacts with the membrane-bound lipoteichoic acid of P. acnes.Small round bodies (SRBs) bound to IgA, IgM, or IgG were detected in sinus macrophages, in 32 (84%), 32 (84%), or 11 (29%) sarcoid samples, respectively, and in 19 (21%), 26 (29%), or no (0%) control samples, respectively. Some of these insoluble immune complexes (IICs) also bound to C1q and C3c. We developed a microwave treatment followed by brief trypsin digestion (MT treatment) to detect PAB-reactive SRBs bound to immunoglobulins (IIC-forming P. acnes). MT treatment revealed abundant IIC-forming P. acnes in most (89%) of the sarcoid samples and sparse distribution in some (20%) of the control samples with lymphadenitis, but no IIC-forming P. acnes was detected in control samples without inflammation. IIC-forming P. acnes were mostly bound to both IgA and IgM. The PAB-reactive antigen and immunoglobulins were both located at the peripheral rim of the IIC-forming P. acnes. Conventional electron microscopy identified many SRBs (0.5-2.0 μm diameter) in sinus macrophages of sarcoid lymph nodes with many IIC-forming P. acnes, some of which were in phagolysosomes with a degraded and lamellar appearance.P. acnes-derived IICs in sinus macrophages were frequent and abundant in sarcoid lymph nodes, suggesting a potential etiologic link between sarcoidosis and this commensal bacterium.
- Published
- 2018
- Full Text
- View/download PDF
19. <scp>Short‐term</scp> safety of an <scp>anti‐severe</scp> acute respiratory syndrome coronavirus 2 messenger <scp>RNA</scp> vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study
- Author
-
Tomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, Shoichi Kuyama, Sayaka Tachibana, Koji Inoue, Kenichi Chikamori, Kenichiro Kudo, Nobuaki Ochi, Daijiro Harada, Yoshinobu Maeda, and Katsuyuki Kiura
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,General Medicine - Published
- 2021
- Full Text
- View/download PDF
20. Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study
- Author
-
Daijiro, Harada, Tomoki, Tamura, Kiichiro, Ninomiya, Toshio, Kubo, Shoichi, Kuyama, Sayaka, Tachibana, Koji, Inoue, Kenichi, Chikamori, Kenichiro, Kudo, Nobuaki, Ochi, Yoshinobu, Maeda, and Katsuyuki, Kiura
- Abstract
COVID-19 incidence is high in patients with cancer. The fatality rate was high for the Delta variant, necessitating infection prevention by vaccination. This study evaluated the safety of a SARS-CoV-2 vaccine in patients with advanced lung cancer receiving anticancer therapy.We prospectively enrolled patients receiving anticancer drugs for advanced lung cancer and planning SARS-CoV-2 vaccination. Early side effects within 7 days of vaccination were evaluated using patient-reported outcome (PRO) surveys. Chi-square test and multivariate logistic regression analyses were used.Post-vaccination PROs were collected from 406 patients (252 were males). The mean age was 72 years. Treatment at the time of initial vaccination included chemotherapy, immune checkpoint inhibitors (ICI), a combination of chemotherapy and ICI, targeted therapy including tyrosine kinase inhibitors, and others in 115, 93, 45, 147, and six cases, respectively. The vaccines administered were BNT162b2 and mRNA273 in 361 and three cases, respectively and unknown in 42 cases. A total of 16.1% of patients developed fever (38°C) after the second mRNA vaccination (95% confidence interval: 12.6%-20.1%). This rate is comparable to data previously reported in 120 patients and slightly higher than that of healthy participants of the BNT162b2 study. Patients receiving treatment with cytotoxic anticancer agents were more likely to have high fever. Multivariate analysis showed no correlation between fever frequency and patient background. No serious initial adverse events due to vaccination were observed.Anti-SARS-CoV-2 mRNA vaccination is safe; however, post-vaccination fever is more common in patients undergoing lung cancer treatment than in healthy individuals.
- Published
- 2022
21. Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report
- Author
-
Masamoto Nakanishi, Tomoki Tamura, Keita Kawakado, Go Makimoto, Shoichi Kuyama, and Yumiko Sato
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pembrolizumab ,Case Reports ,primary salivary gland‐type tumor of the lung ,Bronchoscopy ,Biopsy ,medicine ,case report ,pemetrexed ,Lymphangiomatosis ,RC254-282 ,Lung ,medicine.diagnostic_test ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,respiratory system ,medicine.disease ,medicine.anatomical_structure ,Pemetrexed ,Oncology ,Esophageal stricture ,carboplatin ,Adenocarcinoma ,Radiology ,pembrolizumab ,business ,medicine.drug - Abstract
Primary salivary gland‐type tumors of the lung are rare, accounting for, Lung adenocarcinoma was diagnosed in this patient who subsequently received carboplatin, pemetrexed and pembrolizumab. The carcinomatous lymphangiomatosis improved. Autopsy revealed the tumor was primary salivary gland‐type lung adenocarcinoma.
- Published
- 2021
22. Potential Degradation of 4‐Methyltetrahydropyran (4‐MeTHP) under Oxidation Conditions
- Author
-
Tomoki Tamura and Shoji Kobayashi
- Subjects
Solvent ,Chemistry ,Organic Chemistry ,Degradation (geology) ,Organic chemistry - Published
- 2021
- Full Text
- View/download PDF
23. [Esophageal Perforation on Transesophageal Echocardiography in Open-heart Surgery:Report of a Case]
- Author
-
Yurie, Ohtomo, Tomoki, Tamura, Naoya, Momose, and Tetsuya, Horai
- Subjects
C-Reactive Protein ,Esophageal Perforation ,Prednisolone ,Humans ,Female ,Cardiac Surgical Procedures ,Echocardiography, Transesophageal ,Aged - Abstract
A 70-year-old woman, who was taking prednisolone to treat Takayasu arteritis, underwent surgery for aortic regurgitation and aneurysm of the ascending aorta. The probe of the transesophageal echocardiography (TEE) could not be inserted due to resistance during anesthesia induction and was inserted after starting cardiopulmonary bypass. The right pneumothorax was observed during surgery. After surgery, fever and a high C-reactive protein level continued, and a computed tomography (CT) examination revealed right thoracic empyema together with free air around the esophagus. The esophageal perforation diagnosis was confirmed by upper endoscopy. Esophageal leakage continued despite emergency esophageal repair and enterostomy. Although esophagectomy was performed 2 months later, the patient died 6 months after cardiac surgery due to sepsis. Thus, esophageal perforation related to TEE in open-heart surgery was considered to be associated with a poor prognosis.
- Published
- 2022
24. PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma
- Author
-
Minami Miyauchi, Takumi Akashi, Asuka Furukawa, Keisuke Uchida, Tomoki Tamura, Noboru Ando, Susumu Kirimura, Hiroshi Shintaku, Kurara Yamamoto, Takashi Ito, Keiko Miura, Kou Kayamori, Yosuke Ariizumi, Takahiro Asakage, Atsushi Kudo, Minoru Tanabe, Yasuhisa Fujii, Hironori Ishibashi, Kenichi Okubo, Masanori Murakami, Tetsuya Yamada, Akira Takemoto, Yuan Bae, Yoshinobu Eishi, and Kenichi Ohashi
- Subjects
Paraganglioma ,Paraganglioma, Extra-Adrenal ,Endocrinology ,Endocrinology, Diabetes and Metabolism ,Adrenal Gland Neoplasms ,Humans ,General Medicine ,Pheochromocytoma ,Biomarkers ,Pathology and Forensic Medicine ,Transcription Factors - Abstract
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are non-epithelial neuroendocrine neoplasms originating from the adrenal medulla and paraganglion of the sympathetic and parasympathetic nervous system, respectively. PCCs and PGLs show histological similarities with other epithelial neuroendocrine neoplasms and olfactory neuroblastomas (ONBs), and the differential diagnosis of PGLs is particularly difficult. Therefore, we compared the sensitivity of PHOX2A, PHOX2B, and tyrosine hydroxylase (TH) in the histopathological diagnosis of PCCs and PGLs immunohistochemically using the tissue microarrays of 297 neoplasms including PCCs, PGLs, neuroblastomas, ganglioneuromas, epithelial neuroendocrine neoplasms, and ONBs. Using cutoff values of 25%, 5%, and 5% of tumor cells expressing PHOX2A, PHOX2B, and TH, respectively, as positive, 40 of 51 PCCs, 32 of 33 parasympathetic/head and neck PGLs (HNPGLs), 17 of 19 sympathetic/thoracoabdominal PGLs (TAPGLs), and 12 of 152 epithelial neuroendocrine neoplasms, including 123 well-differentiated and 29 poorly differentiated neuroendocrine neoplasms, were PHOX2A-positive. All 51 PCCs, 33 HNPGLs, and 19 TAPGLs were PHOX2B-positive, while all 152 epithelial neuroendocrine neoplasms were PHOX2B-negative. Moreover, 50 of 51 PCCs, 13 of 33 HNPGLs, all TAPGLs, and 12 of 152 epithelial neuroendocrine neoplasms were TH-positive. All ONBs were negative for PHOX2A, PHOX2B, and TH. PHOX2B was the most sensitive and specific diagnostic marker for PCCs and PGLs among PHOX2A, PHOX2B, and TH. PHOX2B can facilitate identification of PCCs and PGLs from epithelial neuroendocrine neoplasms and ONBs, especially in the case of HNPGLs, in which TH is often negative.
- Published
- 2022
25. More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance
- Author
-
Chihiro Ando, Eiki Ichihara, Toshihide Yokoyama, Koji Inoue, Tomoki Tamura, Keiichi Fujiwara, Naohiro Oda, Hirohisa Kano, Daizo Kishino, Kazuhiko Watanabe, Masaaki Inoue, Nobuaki Ochi, Fumie Onishi, Hirohisa Ichikawa, Hiroshi Kobe, Sayaka Tachibana, Katsuyuki Hotta, Yoshinobu Maeda, and Katsuyuki Kiura
- Subjects
Cancer Research ,Oncology ,General Medicine - Abstract
Combination therapy with immune checkpoint inhibitors (ICIs) and chemotherapy (ICI + chemotherapy) has become the standard first line treatment for driver oncogene-negative advanced non-small-cell lung cancer (NSCLC). However, it may be more toxic compared to monotherapy, which limits its use. Moreover, the feasibility of the combination therapy in clinical practice remains unknown.We conducted a cohort study to determine the implementation rate of ICI + chemotherapy in clinical practice. We retrospectively reviewed clinical data from advanced NSCLC patients who received systemic therapy at 13 institutions between December 2018 and December 2020.After excluding 154 patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene alterations, a total of 919 NSCLC patients were included. Among them, 442 were treated with ICI + chemotherapy (48%), whereas 477 were treated with other therapies (52%). Among these 477 patients, 340 did not receive ICI + chemotherapy because of intolerance (71%); thus, more than one-third of the advanced NSCLC patients do not benefit from the combination therapy due to intolerance. Among the 659 NSCLC patients for whom PD-L1 was 50% or unknown, only 342 received the ICI + chemotherapy combination (52%) even though it is considered preferable to either therapy alone; the remaining 318 patients were treated with other therapies (48%). Among the 318 patients who did not receive ICI + chemotherapy, 274 were intolerant to it (86%).Our results revealed that a substantial proportion of advanced NSCLC patients did not benefit from ICI + chemotherapy due to intolerance. As treatments for NSCLC are moving toward combinations for greater efficacy, their feasibility in clinical practice must be taken into consideration.
- Published
- 2022
26. Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
- Author
-
Shoichi Kuyama, Masamoto Nakanishi, Keita Kawakado, Tomoki Tamura, and Go Makimoto
- Subjects
Male ,medicine.medical_specialty ,Lung Neoplasms ,Optic Neuritis ,Combination therapy ,genetic structures ,Renal function ,Case Report ,Adenocarcinoma of Lung ,Pembrolizumab ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,0302 clinical medicine ,Internal Medicine ,medicine ,Humans ,Optic neuritis ,Lung ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,eye diseases ,Pemetrexed ,medicine.anatomical_structure ,non-small-cell lung cancer ,Adenocarcinoma ,030211 gastroenterology & hepatology ,Radiology ,sense organs ,pembrolizumab ,business ,retrobulbar optic neuritis ,Brain metastasis ,medicine.drug - Abstract
Pembrolizumab is a monoclonal antibody with anti-tumor effects. Only a few reports have previously described retrobulbar optic neuritis induced by pembrolizumab. We herein report the case of a 64 -year-old man with advanced lung adenocarcinoma who received cisplatin, pemetrexed, and pembrolizumab combination therapy for six months. Following treatment, a visual field test showed a left central scotoma. Imaging studies showed left optic neuritis without brain metastasis. Blood tests showed an elevated serum creatinine level. He was diagnosed with retrobulbar optic neuritis and pembrolizumab-induced renal failure. After receiving corticosteroid treatment, his renal function rapidly improved. The optic neuritis improved somewhat, but it was not adequately resolved.
- Published
- 2021
27. Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
- Author
-
Shoichi Kuyama, Masamoto Nakanishi, Keita Kawakado, Tomoki Tamura, and Go Makimoto
- Subjects
0301 basic medicine ,Alectinib ,Oncology ,medicine.medical_specialty ,hepatotoxicity ,Case Report ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,lorlatinib ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Anaplastic lymphoma kinase ,alectinib ,Lung cancer ,Adverse effect ,Ceritinib ,Crizotinib ,business.industry ,anaplastic lymphoma kinase ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Lorlatinib ,030104 developmental biology ,non-small-cell lung cancer ,030220 oncology & carcinogenesis ,Adenocarcinoma ,business ,medicine.drug - Abstract
Alectinib is a key drug for treating anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib. Herein, we describe a case of ALK-positive adenocarcinoma successfully treated with lorlatinib after developing alectinib-induced hepatotoxicity. A 57-year-old Japanese man received alectinib as first-line therapy for ALK-positive NSCLC. After 79 days, alectinib was discontinued because of hepatotoxicity and later restarted at 150 mg/day, inducing hepatotoxicity again after 64 days. Switching to lorlatinib treatment (continued for >4 months) caused no severe adverse effects. Hence, lorlatinib may be useful for patients experiencing alectinib-induced hepatotoxicity.
- Published
- 2021
28. Total Synthesis, Structure Revision, and Neuroprotective Effect of Hericenones C–H and Their Derivatives
- Author
-
Takeshi Yasumoto, Kaoru Nagai, Satoshi Shimizu, Shoji Kobayashi, Tomoki Tamura, Tomoki Kintaka, and Mizuho Koshishiba
- Subjects
Biological Products ,Hericium ,Natural product ,biology ,Bicyclic molecule ,010405 organic chemistry ,Stereochemistry ,Organic Chemistry ,Total synthesis ,Tunicamycin ,010402 general chemistry ,biology.organism_classification ,01 natural sciences ,0104 chemical sciences ,chemistry.chemical_compound ,Neuroprotective Agents ,chemistry ,Structural isomer ,Side chain ,Rearrangement reaction ,Hericium erinaceus - Abstract
The first total syntheses of hericenones C-H and "putative 3-hydroxyhericenone F" were achieved. Highlights of the synthesis include the straightforward construction of the resorcinol core and geranyl side chain, assembly of the natural product skeleton by sequential O-geranylation and a clay/zeolite-mediated O → C rearrangement reaction, and a biomimetic cyclization to form a variety of bicyclic natural hericenones and their congeners. The structure of the "putative 3-hydroxyhericenone F" was revised as the 5-exo cyclization product (named: hericenone Z) of epoxyhericenone C through in-depth analyses of the cyclization modes in addition to NMR spectroscopic studies. To gain insights into the biological functions of geranyl-resorcinols in Hericium erinaceus, potential neuroprotective effects against endoplasmic reticulum (ER) stress-dependent cell death were evaluated systematically to clarify a fundamental structure-activity relationship. Among the compounds assayed, the linoleate-containing hericenone analogue, i.e., the regioisomer of hericene D, was found to possess the most potent neuroprotective effect against tunicamycin and thapsigargin-induced ER stress-dependent cell death.
- Published
- 2021
- Full Text
- View/download PDF
29. Effect of Prophylactic Anti-emetics on Opioid-induced Nausea and Vomiting: A Retrospective Observational Cohort Study
- Author
-
Masamoto Nakanishi, Keita Kawakado, Go Makimoto, Shoichi Kuyama, and Tomoki Tamura
- Subjects
Pharmacology ,Cancer Research ,medicine.medical_specialty ,Vomiting ,Nausea ,business.industry ,Gastrointestinal toxicity ,General Biochemistry, Genetics and Molecular Biology ,Analgesics, Opioid ,Pharmacotherapy ,Opioid ,Internal medicine ,medicine ,Antiemetics ,Humans ,medicine.symptom ,Adverse effect ,Opioid analgesics ,business ,Retrospective Studies ,Research Article ,medicine.drug ,Cohort study - Abstract
Background The guidelines on pharmacotherapy for cancer-related pain advocate active measures against the adverse effects of opioids to increase adherence to medication. However, preventative therapy for the management of nausea and vomiting has not been specified. This study aimed to verify the effects of prophylactic anti-emetics in preventing opioid-induced nausea and vomiting. Patients and methods We conducted a retrospective analysis of cases at our hospital in which oral opioids or patches were initiated for the management of pain due to malignant tumours from January 2017 to September 2019. Results Strong opioids were initiated for 349 patients; of these, data for 298 patients were analysed. A total of 193 patients were on anti-emetic prophylaxis. We found that the group that did not receive anti-emetic prophylaxis was significantly more likely to be prescribed an additional anti-emetic. Conclusion Prophylactic administration of anti-emetics at the time of initiating opioid analgesics may reduce gastrointestinal toxicity.
- Published
- 2021
- Full Text
- View/download PDF
30. Autophagy Induced by Intracellular Infection of Propionibacterium acnes.
- Author
-
Teruko Nakamura, Asuka Furukawa, Keisuke Uchida, Tomohisa Ogawa, Tomoki Tamura, Daisuke Sakonishi, Yuriko Wada, Yoshimi Suzuki, Yuki Ishige, Junko Minami, Takumi Akashi, and Yoshinobu Eishi
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Sarcoidosis is caused by Th1-type immune responses to unknown agents, and is linked to the infectious agent Propionibacterium acnes. Many strains of P. acnes isolated from sarcoid lesions cause intracellular infection and autophagy may contribute to the pathogenesis of sarcoidosis. We examined whether P. acnes induces autophagy. METHODS:Three cell lines from macrophages (Raw264.7), mesenchymal cells (MEF), and epithelial cells (HeLa) were infected by viable or heat-killed P. acnes (clinical isolate from sarcoid lymph node) at a multiplicity of infection (MOI) of 100 or 1000 for 1 h. Extracellular bacteria were killed by washing and culturing infected cells with antibiotics. Samples were examined by colony assay, electron-microscopy, and fluorescence-microscopy with anti-LC3 and anti-LAMP1 antibodies. Autophagy-deficient (Atg5-/-) MEF cells were also used. RESULTS:Small and large (≥5 μm in diameter) LC3-positive vacuoles containing few or many P. acnes cells (LC3-positive P. acnes) were frequently found in the three cell lines when infected by viable P. acnes at MOI 1000. LC3-positive large vacuoles were mostly LAMP1-positive. A few small LC3-positive/LAMP1-negative vacuoles were consistently observed in some infected cells for 24 h postinfection. The number of LC3-positive P. acnes was decreased at MOI 100 and completely abolished when heat-killed P. acnes was used. LC3-positive P. acnes was not found in autophagy-deficient Atg5-/- cells where the rate of infection was 25.3 and 17.6 times greater than that in wild-type Atg5+/+ cells at 48 h postinfection at MOI 100 and 1000, respectively. Electron-microscopic examination revealed bacterial cells surrounded mostly by a single-membrane including the large vacuoles and sometimes a double or multi-layered membrane, with occasional undigested bacterial cells in ruptured late endosomes or in the cytoplasm. CONCLUSION:Autophagy was induced by intracellular P. acnes infection and contributed to intracellular bacterial killing as an additional host defense mechanism to endocytosis or phagocytosis.
- Published
- 2016
- Full Text
- View/download PDF
31. Heerfordt's Syndrome Associated with Trigeminal Nerve Palsy and Reversed Halo Sign
- Author
-
Satoko Makimoto, Masamoto Nakanishi, Tomoki Tamura, Yumiko Sato, Go Makimoto, Keita Kawakado, Shoichi Kuyama, and Minori Noda
- Subjects
Pathology ,medicine.medical_specialty ,Sarcoidosis ,Case Report ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Sarcoidosis, Pulmonary ,Biopsy ,endobronchial ultrasound-guided transbronchial needle aspiration ,Internal Medicine ,medicine ,Humans ,Parotid Gland ,Trigeminal Nerve ,Halo sign ,Uveoparotid Fever ,Palsy ,Lung ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,reversed halo sign ,Parotid gland ,trigeminal nerve palsy ,medicine.anatomical_structure ,030211 gastroenterology & hepatology ,Heerfordt's syndrome ,Lymph ,medicine.symptom ,business ,Uveitis - Abstract
Heerfordt's syndrome is a rare subtype of sarcoidosis and features a combination of facial palsy, parotid swelling, and uveitis, associated with a low-grade fever. Cases with two of three symptoms are called "incomplete Heerfordt's syndrome." Heerfordt's syndrome involving other cranial nerve symptoms is relatively rare. We herein report a case of incomplete Heerfordt's syndrome presenting with trigeminal nerve palsy and a reversed halo sign, a rare manifestation of pulmonary sarcoidosis. The histological diagnosis following a biopsy of the parotid gland and endobronchial ultrasound-guided trans-bronchial needle aspiration of the mediastinal lymph nodes was sarcoidosis. The symptoms and lung lesions improved after corticosteroid therapy.
- Published
- 2020
32. Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
- Author
-
Go Makimoto, Tatsuya Nishi, Kenichiro Kudo, Tomoka Nishimura, Keita Kawakado, Shoichi Kuyama, and Tomoki Tamura
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Urticaria ,medicine.medical_treatment ,Antineoplastic Agents ,EGFR T790M ,030204 cardiovascular system & hematology ,03 medical and health sciences ,T790M ,0302 clinical medicine ,Asian People ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Osimertinib ,Epidermal growth factor receptor ,Lung cancer ,Adverse effect ,Desensitization (medicine) ,Aged, 80 and over ,Acrylamides ,Aniline Compounds ,biology ,business.industry ,General Medicine ,medicine.disease ,respiratory tract diseases ,ErbB Receptors ,Mutation ,biology.protein ,Female ,030211 gastroenterology & hepatology ,Non small cell ,business - Abstract
Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for >12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria.
- Published
- 2020
- Full Text
- View/download PDF
33. A Case of IgG4-Related Disease with Pleural Effusion, Requiring Exclusion of Tuberculous Pleurisy
- Author
-
Susumu Doita, Tomoki Tamura, Takahiro Baba, Hiroki Oomori, Kazuya Nishii, Masamoto Nakanishi, and Shoichi Kuyama
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
- Full Text
- View/download PDF
34. The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study
- Author
-
Tomoka Nishimura, Eiki Ichihara, Toshihide Yokoyama, Koji Inoue, Tomoki Tamura, Ken Sato, Naohiro Oda, Hirohisa Kano, Daizo Kishino, Haruyuki Kawai, Masaaki Inoue, Nobuaki Ochi, Nobukazu Fujimoto, Hirohisa Ichikawa, Chihiro Ando, Katsuyuki Hotta, Yoshinobu Maeda, and Katsuyuki Kiura
- Subjects
immune checkpoint inhibitors ,pleural effusion ,non-small cell carcinoma ,Cancer Research ,Oncology - Abstract
Simple Summary Minimal data exists on pleural effusion (PE) for non-small cell lung cancer (NSCLC) patients undergoing combined ICI and chemotherapy. We retrospectively investigated how PE affects survival outcomes in patients with NSCLC undergoing this combined therapy. We identified 478 patients who underwent combined ICI therapy and chemotherapy; 357 patients did not have PE, and 121 patients did have PE. Patients with PE had significantly shorter progression-free survival and overall survival than those without PE. In addition, bevacizumab-containing regimens did not improve the survival outcomes for patients with PE. In conclusion, PE was associated with poor outcomes among patients with NSCLC undergoing combined ICI therapy and chemotherapy. Objectives: Combined immune checkpoint inhibitor (ICI) therapy and chemotherapy has become the standard treatment for advanced non-small-cell lung cancer (NSCLC). Pleural effusion (PE) is associated with poor outcomes among patients with NSCLC undergoing chemotherapy. However, minimal data exists on PE for patients undergoing combined ICI and chemotherapy. Therefore, we investigated how PE affects survival outcomes in patients with NSCLC undergoing this combined therapy. Methods: We identified patients with advanced NSCLC undergoing chemotherapy and ICI therapy from the Okayama Lung Cancer Study Group-Immune Chemotherapy Database (OLCSG-ICD) between December 2018 and December 2020; the OLCSG-ICD includes the clinical data of patients with advanced NSCLC from 13 institutions. Then, we analyzed the treatment outcomes based on the presence of PE. Results: We identified 478 patients who underwent combined ICI therapy and chemotherapy; 357 patients did not have PE, and 121 patients did have PE. Patients with PE had significantly shorter progression-free survival (PFS) and overall survival (OS) than those without PE (median PFS: 6.2 months versus 9.1 months; p < 0.001; median OS: 16.4 months versus 27.7 months; p < 0.001). The negative effect of PE differed based on the patient's programmed cell death-ligand 1 (PD-L1) expression status; with the effect being more evident in patients with high PD-L1 expression. In addition, PFS and OS did not differ between patients who did and did not undergo bevacizumab treatment; thus, bevacizumab-containing regimens did not improve the survival outcomes for patients with PE. Conclusion: PE is associated with poor outcomes among patients with NSCLC undergoing combined ICI therapy and chemotherapy.
- Published
- 2022
- Full Text
- View/download PDF
35. 4‐Methyltetrahydropyran (4‐MeTHP): Application as an Organic Reaction Solvent
- Author
-
Tomoki Tamura, Shoji Kobayashi, Saki Yoshimoto, Takashi Kawakami, and Araki Masuyama
- Subjects
Green chemistry ,radical ,Full Paper ,010405 organic chemistry ,Chemistry ,2-Methyltetrahydrofuran ,Organic Chemistry ,organic reaction ,General Chemistry ,Full Papers ,010402 general chemistry ,Metathesis ,01 natural sciences ,Biochemistry ,green solvent ,0104 chemical sciences ,Solvent ,chemistry.chemical_compound ,4-methyltetrahydropyran ,Organic reaction ,Wittig reaction ,Degradation (geology) ,Organic chemistry ,Lewis acids and bases ,2-methyltetrahydrofuran - Abstract
4‐Methyltetrahydropyran (4‐MeTHP) is a hydrophobic cyclic ether with potential for industrial applications. We herein report, for the first time, a comprehensive study on the performance of 4‐MeTHP as an organic reaction solvent. Its broad application to organic reactions includes radical, Grignard, Wittig, organometallic, halogen‐metal exchange, reduction, oxidation, epoxidation, amidation, esterification, metathesis, and other miscellaneous organic reactions. This breadth suggests 4‐MeTHP can serve as a substitute for conventional ethers and harmful halogenated solvents. However, 4‐MeTHP was found incompatible with strong Lewis acids, and the C−O bond was readily cleaved by treatment with BBr3. Moreover, the radical‐based degradation pathways of 4‐MeTHP, THP and 2‐MeTHF were elucidated on the basis of GC‐MS analyses. The data reported herein is anticipated to be useful for a broad range of synthetic chemists, especially industrial process chemists, when selecting the reaction solvent with green chemistry perspectives., Organic pastures greener: A comprehensive study on the performance of 4‐methyltetrahydropyran (4‐MeTHP) as a reaction solvent is described. The broad applications and higher stability under free‐radical conditions make this solvent a promising alternative to common organic solvents. This study provides key data for process chemists in choosing a reaction solvent under green chemistry perspectives.
- Published
- 2019
36. A Case of Ovarian Metastasis from ALK-rearranged Lung Adenocarcinoma in an Elderly Woman Who Resumed Menstruation due to Estradiol Production
- Author
-
Tomoki Tamura, Tatsuya Nishi, Kenichiro Kudo, Keita Kawakado, Shoichi Kuyama, and Tomoka Kawajiri
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Lung ,business.industry ,medicine.disease ,Menstruation ,medicine.anatomical_structure ,Ovarian metastasis ,Internal medicine ,medicine ,Adenocarcinoma ,business - Published
- 2019
- Full Text
- View/download PDF
37. Catalase expression of Propionibacterium acnes may contribute to intracellular persistence of the bacterium in sinus macrophages of lymph nodes affected by sarcoidosis
- Author
-
Tomonari Amano, Nobuyasu Awano, Asuka Furukawa, Takashi Ito, Keisuke Uchida, Tomoki Tamura, Kurara Yamamoto, Akira Hebisawa, Tamiko Takemura, Tomoya Kakegawa, Takumi Akashi, Yuki Ishige, Daisuke Kobayashi, Yoshinobu Eishi, and Mariko Negi
- Subjects
Adult ,Male ,0301 basic medicine ,Sarcoidosis ,Biopsy ,Immunology ,Fluorescent Antibody Technique ,Gene Expression ,Microbiology ,03 medical and health sciences ,Propionibacterium acnes ,0302 clinical medicine ,Immune system ,Antigen ,Antibody Specificity ,medicine ,Humans ,Aged ,030203 arthritis & rheumatology ,Bacteria ,biology ,Chemistry ,Macrophages ,Middle Aged ,Catalase ,biology.organism_classification ,medicine.disease ,Antibodies, Bacterial ,Immunohistochemistry ,Oxidative Stress ,030104 developmental biology ,biology.protein ,Female ,Lymph Nodes ,Lymph ,Lipoteichoic acid ,Antibody - Abstract
Bacterial catalase is important for intracellular survival of the bacteria. This protein of Propionibacterium acnes, one of possible causes of sarcoidosis, induces hypersensitive Th1 immune responses in sarcoidosis patients. We examined catalase expression in cultured P. acnes isolated from 19 sarcoid and 18 control lymph nodes and immunohistochemical localization of the protein in lymph nodes from 43 sarcoidosis and 102 control patients using a novel P. acnes-specific antibody (PAC) that reacts with the catalase protein, together with the previously reported P. acnes-specific PAB and TIG antibodies. High catalase expression of P. acnes cells was found during stationary phase in more isolates from sarcoid than from non-sarcoid lymph nodes and was associated with bacterial survival under H2O2-induced oxidative stress. In many sarcoid and some control lymph nodes, catalase expression was detected at the outer margins of PAB-reactive Hamazaki-Wesenberg (HW) bodies in sinus macrophages, the same location as catalase expression on the surface of cultured P. acnes and the same distribution as bacterial cell membrane-bound lipoteichoic acid in HW bodies. Some or no catalase expression was detected in sarcoid granulomas with PAB reactivity or in clustered paracortical macrophages packed with many PAB-reactive small-round bodies. HW bodies expressing catalase may be persistent P. acnes in sinus macrophages whereas PAB-reactive small-round bodies with undetectable catalase may be activated P. acnes proliferating in paracortical macrophages. Intracellular proliferation of P. acnes in paracortical macrophages may lead to granuloma formation by this commensal bacterium in sarcoidosis patients with Th1 hypersensitivity to certain P. acnes antigens, including catalase.
- Published
- 2019
- Full Text
- View/download PDF
38. A Case of Small Cell Lung Cancer with an Epidermal Growth Factor Receptor T790M Mutation That Responded to Osimertinib
- Author
-
Shoichi Kuyama, Chiaki Matsumoto, Tatsuya Nishi, Kenichiro Kudo, Tomoki Tamura, and Tomoka Kawajiri
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,business.industry ,Mutation (genetic algorithm) ,Cancer research ,Medicine ,Osimertinib ,Epidermal Growth Factor Receptor T790M ,Non small cell ,business - Published
- 2019
- Full Text
- View/download PDF
39. Transcatheter embolization for idiopathic peripheral pulmonary arterial aneurysm: A case report
- Author
-
Shoichi Kuyama, Tomoka Kawajiri, Tomoki Tamura, Takayuki Yabuki, Tatsuya Nishi, and Kenichiro Kudo
- Subjects
hydrogel‐coated metallic coil ,medicine.medical_specialty ,Transcatheter embolization ,medicine.medical_treatment ,Case Report ,Case Reports ,embolization ,030204 cardiovascular system & hematology ,AVP 4 ,Sudden death ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,In patient ,Embolization ,peripheral pulmonary arterial aneurysm ,business.industry ,Arterial aneurysm ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,Peripheral ,Surgery ,Natural history ,Arterial aneurysms ,030220 oncology & carcinogenesis ,business - Abstract
Key Clinical Message The natural history of idiopathic peripheral pulmonary arterial aneurysms (PAAs) is unclear; however, they can cause sudden death by rupture. Our case illustrates the utility and low invasiveness of transcatheter embolization using an AMPLATZER™ Vascular Plug 4 and hydrogel‐coated metallic coils in patients with idiopathic peripheral PAAs.
- Published
- 2019
40. Successful transcatheter arterial embolization of asymptomatic aneurysm associated with left inferior phrenic artery-to-left pulmonary artery fistula: A case report
- Author
-
Go Makimoto, Tatsuya Nishi, Masamoto Nakanishi, Takayuki Yabuki, Shoichi Kuyama, Tomoki Tamura, and Keita Kawakado
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Fistula ,Case Report ,Asymptomatic ,03 medical and health sciences ,Diseases of the respiratory system ,0302 clinical medicine ,Aneurysm ,medicine.artery ,Medicine ,TAE, Transcatheter arterial embolization ,medicine.diagnostic_test ,RC705-779 ,business.industry ,Arterial Embolization ,Left pulmonary artery ,medicine.disease ,CT, computed tomography ,Transcatheter arterial embolization ,medicine.anatomical_structure ,Inferior phrenic artery-to-pulmonary artery fistula ,030228 respiratory system ,030220 oncology & carcinogenesis ,Pulmonary artery ,Angiography ,Radiology ,medicine.symptom ,business ,Artery - Abstract
Cases of inferior phrenic artery-to-pulmonary artery fistulas and those complicated by massive hemoptysis have been rarely reported. A 38-year-old man presented to our hospital with a chief complaint of coughing. Computed tomography (CT) revealed a nodule in the left lower lobe, and contrast-enhanced CT showed inflow of contrast medium into the nodule. CT angiography detected an aneurysm associated with a left inferior phrenic artery-to-left pulmonary artery fistula. Transcatheter arterial embolization (TAE) was performed to prevent hemoptysis. Hemoptysis did not occur during the 2-year follow-up. We report a rare case of asymptomatic aneurysm associated with a left inferior phrenic artery-to-left pulmonary artery fistula, which was successfully treated using TAE to prevent hemoptysis.
- Published
- 2021
41. Successful corticosteroid treatment of necrotizing sarcoid granulomatosis associated with tracheal lesion recurred after a surgical lung biopsy
- Author
-
Tomoki Tamura, Go Makimoto, Keita Kawakado, Masamoto Nakanishi, Shoichi Kuyama, and Yumiko Sato
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Tuberculosis ,Necrosis ,Case Report ,Lung biopsy ,Necrotizing sarcoid granulomatosis ,Tracheal lesion ,Lesion ,Diseases of the respiratory system ,Bronchoscopy ,Recurrence ,medicine ,Corticosteroid ,Lung ,medicine.diagnostic_test ,RC705-779 ,business.industry ,respiratory system ,medicine.disease ,Necrotizing sarcoid granulomatosis (NSG), chest computed tomography (CT) ,medicine.anatomical_structure ,Radiology ,Sarcoidosis ,medicine.symptom ,business ,Rare disease - Abstract
Necrotizing sarcoid granulomatosis (NSG) is a rare disease that presents with nodular lung lesions and necrosis. The pathology is consistent with sarcoidosis, but the necrosis can lead to a diagnosis of tuberculosis. Herein, we report a rare case of NSG that recurred four years after the initial diagnosis was made by surgical lung biopsy. A 51-year-old woman was initially referred to our hospital for the evaluation of multiple lung nodules. The pathological evaluation of a lung biopsy showed granulomas with necrosis and the infiltration of lymphocytes; thus, she was diagnosed with NSG. The lung nodules gradually improved after the diagnosis and we continued to follow her even though she did not require treatment. Four years after her initial diagnosis, she complained of back pain. Upon evaluation, we found that multiple lung nodules had recurred. Bronchoscopy also revealed a tracheal polypoid lesion, which showed granulomas with necrosis pathologically. Therefore, we diagnosed her with the recurrence of NSG. After the corticosteroid therapy, multiple lung nodules drastically improved. NSG patients should be carefully followed-up over several years, even if they do not require treatment.
- Published
- 2021
42. Epithelioid Cell Granulomas in Crohn's Disease Are Differentially Associated With Blood Vessels and Lymphatic Vessels: A Sequential Double Immunostaining Study
- Author
-
Takashi Yao, Daisuke Kobayashi, Tomoki Tamura, Tetsuo Yamana, Keiko Abe, Makoto Kodama, Satomi Furukawa, Rikisaburo Sahara, and Soh Okano
- Subjects
0301 basic medicine ,Adult ,Male ,Pathology ,medicine.medical_specialty ,Histology ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Crohn Disease ,hemic and lymphatic diseases ,Lymphatic vessel ,medicine ,Humans ,Lymphatic Vessels ,Granuloma ,Staining and Labeling ,business.industry ,Epithelioid Cells ,Histiocytes ,Articles ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,Lymphatic system ,Lymphangitis ,Gastrointestinal disorder ,cardiovascular system ,Blood Vessels ,030211 gastroenterology & hepatology ,Female ,Anatomy ,business ,Vasculitis ,Epithelioid cell ,Blood vessel - Abstract
Crohn’s disease (CD) is a gastrointestinal disorder of unknown etiology. CD-specific longitudinal ulcers show an association between disease pathogenesis and vasculature dysfunction. Granulomatous lymphangitis may also contribute to CD pathogenesis; meanwhile, vasculitis is the primary CD lesion. We investigated the association between granulomas and lymphatic and blood vessels to assess the role of vasculature in CD pathogenesis. Two small and large intestine specimens were obtained from four CD patients. From each specimen, 160 sequential sections were obtained and double immunohistochemical stained to label lymphatic and blood vessels in association with granulomas. We found that 289 of 342 granulomas (85%) were associated with a lymphatic vessel and 313 of 364 granulomas (86%) were associated with a blood vessel. Although intrablood vessel granulomas were not detected, intralymphatic vessel granulomas were. In the internal region of the granuloma, we found more blood vessels than lymphatic vessels. Hence, these results cumulatively demonstrate that CD epithelioid cell granulomas are differentially associated with lymphatic and blood vessels, suggesting both as essential for the formation and maintenance of these granulomas. Moreover, both lymphatic and blood vessels may participate in granulomatous inflammation in the primary CD lesions; however, additional studies with larger numbers of participants are required to validate our findings.
- Published
- 2020
43. Analysis of damped vibration and sound radiation for structures having a porous layer sandwiched by double walls with an acoustic black hole
- Author
-
Tomoki TAMURA, Takao YAMAGUCHI, Chihiro KAMIO, and Yuta HISAMURA
- Subjects
General Energy - Published
- 2022
- Full Text
- View/download PDF
44. Minimally Invasive Cardiac Surgery for Partial Anomalous Pulmonary Venous Return to the High Portion of the Superior Vena Cava
- Author
-
Yuta Tsuchida, Ko Shibata, and Tomoki Tamura
- Subjects
medicine.medical_specialty ,Superior vena cava ,business.industry ,Internal medicine ,Minimally invasive cardiac surgery ,medicine ,Partial anomalous pulmonary venous return ,Cardiology ,business - Published
- 2018
- Full Text
- View/download PDF
45. Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations
- Author
-
Yoshinobu Maeda, Yuka Kato, Tomoki Tamura, Katsuyuki Kiura, Takehiro Tanaka, Eiki Ichihara, Koichi Ichimura, Kiichiro Ninomiya, Katsuyuki Hotta, Kadoaki Ohashi, Go Makimoto, Hiroko Gotoda, and Toshio Kubo
- Subjects
Male ,0301 basic medicine ,Oncology ,Lung Neoplasms ,medicine.medical_treatment ,Biochemistry ,0302 clinical medicine ,Japan ,Risk Factors ,Epidermal growth factor ,Carcinoma, Non-Small-Cell Lung ,Prevalence ,Aged, 80 and over ,biology ,Hazard ratio ,Gefitinib ,Middle Aged ,ErbB Receptors ,Survival Rate ,Treatment Outcome ,Cytokine ,030220 oncology & carcinogenesis ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Biophysics ,Antineoplastic Agents ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Genetic Predisposition to Disease ,Lung cancer ,Interleukin 6 ,Molecular Biology ,Aged ,Interleukin-6 ,business.industry ,Therapeutic effect ,Cell Biology ,medicine.disease ,respiratory tract diseases ,030104 developmental biology ,Mutation ,Immunology ,Quinazolines ,biology.protein ,business ,Immunostaining - Abstract
Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a key therapy used for patients with EGFR-mutant non-small cell lung cancer (NSCLC), some of whom do not respond well to its therapy. Cytokine including IL-6 secreted by tumour cells is postulated as a potential mechanism for the primary resistance or low sensitivity to EGFR-TKIs. Fifty-two patients with advanced EGFR-mutant NSCLC who had received gefitinib were assessed retrospectively. The protein expression of IL-6 in the tumour cells was assessed by immunostaining and judged as positive if ≥ 50 of 100 tumour cells stained positively. Of the 52 patients, 24 (46%) and 28 (54%) were defined as IL-6-postitive (group P) and IL-6-negative (group N), respectively. Group P had worse progression-free survival (PFS) than that of group N, which was retained in the multivariate analysis (hazard ratio: 2.39; 95 %CI: 1.00-5.68; p 0.05). By contrast, the PFS after platinum-based chemotherapy did not differ between groups P and N (p = 0.47). In cell line-based model, the impact of IL-6 on the effect of EGFR-TKIs was assessed. The combination of EGFR-TKI and anti-IL-6 antibody moderately improved the sensitivity of EGFR-TKI in lung cancer cell with EGFR mutation. Interestingly, suppression of EGFR with EGFR-TKI accelerated the activation of STAT3 induced by IL-6. Taken together, tumour IL-6 levels might indicate a subpopulation of EGFR-mutant NSCLC that benefits less from gefitinib monotherapy.
- Published
- 2018
- Full Text
- View/download PDF
46. Cover Feature: Potential Degradation of 4‐Methyltetrahydropyran (4‐MeTHP) under Oxidation Conditions (Asian J. Org. Chem. 10/2021)
- Author
-
Shoji Kobayashi and Tomoki Tamura
- Subjects
Feature (computer vision) ,Chemistry ,Computational chemistry ,Organic Chemistry ,Degradation (geology) ,Cover (algebra) - Published
- 2021
- Full Text
- View/download PDF
47. A Diversity-Oriented Library of Fluorophore-Modified Receptors Constructed from a Chemical Library of Synthetic Fluorophores
- Author
-
Young-Tae Chang, Tomoki Tamura, Eiji Nakata, Shun Nakano, Raj Kumar Das, and Takashi Morii
- Subjects
Fluorophore ,Molecular Structure ,010405 organic chemistry ,Organic Chemistry ,Biosensing Techniques ,010402 general chemistry ,01 natural sciences ,Biochemistry ,Fluorescence ,Combinatorial chemistry ,Thiol group ,0104 chemical sciences ,Chemical library ,Small Molecule Libraries ,chemistry.chemical_compound ,Adenosine Triphosphate ,Ribonucleoproteins ,chemistry ,Molecular Medicine ,Receptor ,Molecular Biology ,Biosensor ,Fluorescent Dyes ,Rev peptide - Abstract
The practical application of biosensors can be determined by evaluating the sensing ability of fluorophore-modified derivatives of a receptor with appropriate recognition characteristics for target molecules. One of the key determinants for successfully obtaining a useful biosensor is wide variation in the fluorophores attached to a given receptor. Thus, using a larger fluorophore-modified receptor library provides a higher probability of obtaining a practically useful biosensor. However, no effective method has yet been developed for constructing such a diverse library of fluorophore-modified receptors. Herein, we report a method for constructing fluorophore-modified receptors by using a chemical library of synthetic fluorophores with a thiol-reactive group. This library was converted into a library of fluorophore-modified adenosine-binding ribonucleopeptide (RNP) receptors by introducing the fluorophores to the Rev peptide of the RNP complex by alkylation of the thiol group. This method enabled the construction of 263 fluorophore-modified ATP-binding RNP receptors and allowed the selection of suitable receptor-based fluorescent sensors that target ATP.
- Published
- 2017
- Full Text
- View/download PDF
48. Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
- Author
-
Tomoka Kawajiri, Shoichi Kuyama, Keita Kawakado, Tomoki Tamura, Mitsune Tanimoto, Tatsuya Nishi, Kenichiro Kudo, and Go Makimoto
- Subjects
Oncology ,medicine.medical_specialty ,Metastatic lesions ,Central nervous system ,030204 cardiovascular system & hematology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,medicine ,Epidermal growth factor receptor ,Lung cancer ,biology ,business.industry ,Treatment options ,General Medicine ,medicine.disease ,Dacomitinib ,respiratory tract diseases ,medicine.anatomical_structure ,chemistry ,Egfr mutation ,biology.protein ,030211 gastroenterology & hepatology ,business ,Brain metastasis - Abstract
The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutation-positive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.
- Published
- 2020
- Full Text
- View/download PDF
49. Stereocontrolled Total Synthesis of (+)-Isolaurenidificin and (-)-Bromlaurenidificin
- Author
-
Tomoki Tamura, Araki Masuyama, Ryo Yoneyama, Yutaka Hori, and Shoji Kobayashi
- Subjects
Olefin fiber ,010405 organic chemistry ,Stereochemistry ,Organic Chemistry ,Total synthesis ,010402 general chemistry ,01 natural sciences ,Nmr data ,0104 chemical sciences ,Stereocenter ,chemistry.chemical_compound ,chemistry ,Stereoselectivity ,Tetrahydrofuran ,Cis–trans isomerism ,Octane - Abstract
We report the first total syntheses of (+)-isolaurenidificin (1) and (-)-bromlaurenidificin (2), the latest acetogenins of the 2,6-dioxabicyclo[3.3.0]octane class. The synthesis features a completely stereoselective one-pot epimerization-ring contraction to establish the cis configuration with respect to C10-H and C12-H of the tetrahydrofuran ring. Six stereogenic centers and an olefin geometry were constructed in a highly stereoselective manner. Absolute configurations of the natural products were deduced by the comparison of NMR data and specific rotations.
- Published
- 2019
50. CHAC1 overexpression in human gastric parietal cells with Helicobacter pylori infection in the secretory canaliculi
- Author
-
Yoshinobu Eishi, Tomohisa Ogawa, Keisuke Kitagaki, Keisuke Uchida, Takashige Suzuki, Kosuke Takemura, Yuriko Wada, Yutaka Tokairin, Philip G. Board, Tomoki Tamura, and Yasuaki Nakajima
- Subjects
medicine.drug_class ,Somatic cell ,cation transport regulator 1 ,Monoclonal antibody ,Bone canaliculus ,Helicobacter Infections ,03 medical and health sciences ,0302 clinical medicine ,Parietal Cells, Gastric ,medicine ,Gastric mucosa ,Humans ,biology ,Helicobacter pylori ,Chemistry ,gastric cancer ,Gastroenterology ,Cancer ,parietal cells ,General Medicine ,Original Articles ,biology.organism_classification ,medicine.disease ,Molecular biology ,Infectious Diseases ,medicine.anatomical_structure ,Gastric Mucosa ,030220 oncology & carcinogenesis ,Immunohistochemistry ,030211 gastroenterology & hepatology ,Original Article ,secretary canaliculi ,Cation transport ,gamma-Glutamylcyclotransferase - Abstract
Background Cation transport regulator 1 (CHAC1), a newly discovered enzyme that degrades glutathione, is induced in Helicobacter pylori (H. pylori)‐infected gastric epithelial cells in culture. The CHAC1‐induced decrease in glutathione leads to an accumulation of reactive oxygen species and somatic mutations in TP53. We evaluated the possible correlation between H. pylori infection and CHAC1 expression in human gastric mucosa. Materials and Methods Both fresh‐frozen and formalin‐fixed paraffin‐embedded tissue samples of gastric mucosa with or without H. pylori infection were obtained from 41 esophageal cancer patients that underwent esophago‐gastrectomy. Fresh samples were used for real‐time polymerase chain reaction for H. pylori DNA and CHAC1 mRNA, and formalin‐fixed samples were used for immunohistochemistry with anti‐CHAC1 and anti‐H. pylori monoclonal antibodies. Double‐enzyme or fluorescence immunohistochemistry and immuno‐electron microscopy were used for further analysis. Results Significant CHAC1 overexpression was detected in H. pylori‐infected parietal cells that expressed the human proton pump/H,K‐ATPase α subunit, whereas a constitutively low level of CHAC1 mRNA expression was observed in the other samples regardless of the H. pylori infection status, reflecting the weak CHAC1 expression detected by immunohistochemistry in the fundic‐gland areas. Immuno‐electron microscopy revealed intact H. pylori cells in the secretory canaliculi of infected parietal cells. Some parietal cells exhibited positive nuclear signals for Ki67 in the neck zone of the gastric fundic‐gland mucosa with H. pylori infection. Conclusion Cation transport regulator 1 overexpression in H. pylori‐infected parietal cells may cause the H. pylori‐induced somatic mutations that contribute to the development of gastric cancer.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.